Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2017

View Archived Issues

Galapagos initiates phase I trial of cystic fibrosis C2 corrector GLPG-3221

First subject dosed in phase III study of Nevakar's ophthalmic solution for myopia in children

Novel COMT inhibitors as candidates for dopaminergic-related cognitive and motor deficits

BTRX-335140, a potent and reversible KOR antagonist with promising in vivo activity

LDN/OSU-215111 shows promise in preclinical models of Alzheimer's disease and Gulf War illness

Beactica receives funding to develop novel and potent allosteric LSD1 modulators

Supplemental NDA seeks to expand Trelegy Ellipta label in U.S.

Prometic Life Sciences reports interim data from IVIG phase III trial

Teijin's TEI-A reduces uric acid levels in preclinical tests

Rupafin set for Japanese launch

Shionogi & Co. patents new AMPK activators for diabetes

Phase II trials of milciclib in thymic carcinoma and thymoma meet primary endpoints

Bavencio launched in Japan

Perrigo completes divestiture of API business

Innate Pharma offers update on lirilumab program

Sage Therapeutics discloses novel NMDA receptor modulators

Shenogen Pharma and Lee's Pharm collaborate to develop combination product for late-stage cancer

Fochon Pharma presents novel CDK4/6 inhibitors

DSMB recommends continuation of RESOLVE-IT study of elafibranor in NASH

Immunovaccine discloses vaccine compositions for cancer

European Commission approves Tremfya

New vasopressin receptor antagonists presented by Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...